Skip to main content

Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event During J.P. Morgan Healthcare Conference in San Francisco in January 2023

Written by Customer Service on . Posted in Public Companies.

JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau,” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the Company plans to present at the Biotech Showcase™ and host institutional investor meetings at this event, as well as at the LifeSci Partners Corporate Access Event. Both in-person events are taking place in parallel with the 41st Annual J.P. Morgan Healthcare Conference which will be held January 9-12, 2023 in San Francisco, California.

Biotech Showcase:
Raphi Levy, Chief Financial Officer, will provide an overview of the Company, including its Alpha DaRT technology, recent pre-clinical and clinical progress, and upcoming clinical trials including its U.S. multi-center pivotal trial in recurrent cutaneous squamous cell carcinoma. Uzi Sofer, CEO of Alpha Tau and Raphi Levy will also host 1×1 institutional investor meetings.

Date/Time: Monday January 9, 2023, at 3 pm PT
Location: Hilton San Francisco Union Square in San Francisco; Yosemite A (Ballroom Level)
To schedule a meeting, investors can register on the Biotech Showcase website

LifeSci Partners Corporate Access Event:
Uzi Sofer, CEO and Raphi Levy, CFO will be hosting 1×1 institutional investor meetings.

Date: Tuesday, January 10, 2023
Location: Beacon Grand Hotel in San Francisco
To schedule a meeting on the online system managed by LifeSci Partners, please click here to register for the conference.

About Alpha DaRT™

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

Investor Relations Contact

IR@alphatau.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.